AnaptysBio sells portion of drug royalties to Sagard for $250m

San Diego-based clinical-stage biotechnology company AnaptysBio has agreed to monetize a portion of the future royalties and milestones for its cancer drug Jemperli.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this